Evidence map›Paper›PMID 41726147›Full record

ArticleOpen medicine (Warsaw, Poland)2026

Prognostic value of vascular endothelial growth factor subtypes and risk models constructed based on the common pathway of ulcerative colitis and colon cancer.

Shuni Chen, Haibin He, Yonghua Chen, Xunzhen Xu, Pei Liu, Feng Li

Abstract read
In one paragraph

Article in Open medicine (Warsaw, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shuni ChenShenzhen Hospital of Beijing University of Chinese Medicine (Longgang), Shenzhen, GuangDong, China.
Haibin HeShenzhen Hospital of Beijing University of Chinese Medicine (Longgang), Shenzhen, GuangDong, China.ORCID https://orcid.org/0009-0003-4472-8140
Yonghua ChenDepartment of Endocrinology, The Second People's Hospital of Guizhou Province, Guiyang, China.ORCID https://orcid.org/0009-0002-5918-4695
Xunzhen XuShenzhen Hospital of Beijing University of Chinese Medicine (Longgang), Shenzhen, GuangDong, China.ORCID https://orcid.org/0009-0004-2854-527X
Pei LiuResource Institute for Chinese & Ethnic Materia Medica, Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China.ORCID https://orcid.org/0009-0006-9306-6261
Feng LiShenzhen Hospital of Beijing University of Chinese Medicine (Longgang), Shenzhen, GuangDong, China.ORCID https://orcid.org/0009-0002-9162-5606

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Patients with long-term ulcerative colitis (UC) have a significantly increased risk of colon cancer compared to normal individuals. By analyzing the pathways of ulcerative colitis and colon cancer, we identified a common risk pathway - Vascular Endothelial Growth Factor (VEGF). Methods: Based on the Gene Set Variation Analysis (GSVA) scores of the VEGF pathway in colon cancer patients, we divided them into three groups: high, medium, and low. We performed clinical characteristic and immune-related analyses on these three groups, conducted differential gene analysis, performed univariate and multivariate Cox analyses on the differential genes to screen out gene signatures. A risk model was constructed and validated in the UC cohort. Colon cancer patients were classified into high-and low-risk groups based on risk scores, clinical characteristics, immune microenvironment, immunotherapy, and drug sensitivity were analyzed for both groups. Results: The high expression group had higher clinical staging and pathologic staging, higher immune microenvironment scores, and greater immune cell content. The risk model we constructed demonstrated good prognostic predictive ability not only for colon cancer but also for UC. The high-risk group had a lower survival rate, while the low-risk group had a better response to immunotherapy. Conclusions: These findings provide new insights into the treatment of colon cancer.

Indexed as

colon cancerimmunotherapyrisk modelulcerative colitis (UC)vascular endothelial growth factor

Identifiers

PMID41726147
PMCPMC12917561

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.